Portfolio News
Sofinnova MD Start
ELSAN partners with Sofinnova MD Start III, an acceleration fund dedicated to healthcare innovation and medical devices
This collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
Related Strategy
MD StartRelated Deal lead
Anne OsdoitThis collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
June 25, 2020 - PARIS, France -
ELSAN, a leader in the private hospital sector in France, announces a strategic partnership with the Sofinnova MD START III acceleration fund. Through this partnership, ELSAN becomes an investor in the acceleration fund co-created and managed by Sofinnova Partners, a leading European venture capital firm, and offers its healthcare practitioners the means to accelerate the development of their medical device innovations for the benefit of patients.
"We are delighted that ELSAN is joining Sofinnova MD Start III as a community of clinical investigators and experts," commented Anne Osdoit, Partner at Sofinnova Partners.
Related News
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Bioptimus Strengthens Commercial and Scientific Leadership with Key Hires
Pi-Cardia’s ShortCut™ becomes First Leaflet Modification Technology to receive CMS NTAP for Valve-in-Valve TAVR
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Nuage Therapeutics welcomes Olivier Corminboeuf and Blandine Guimet to Leadership Team